A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + NALIRI and 5-FU
+ NALIRINOX for metastatic pancreatic ductal adenocarcinoma (PDAC), progressive after
Gemcitabine-Abraxane or Gemcitabine monotherapy